
Beyond the Scales: The Fight to Halt Cachexia
Affecting up to 80% of cancer patients, cachexia remains a stubborn adversary with limited treatment options. A recent summit in Washington signalled a regulatory pivot: success is no longer measured by muscle mass alone, but by the restoration of daily function and independence.
By Fioretti, von Haehling, Coats, Butler, Del Fabbro, Skipworth, Laird, Anker


